Diagnostic biomarkers for active tuberculosis: progress and challenges.
active TB
biomarkers
diagnostic biomarkers
tuberculosis
Journal
EMBO molecular medicine
ISSN: 1757-4684
Titre abrégé: EMBO Mol Med
Pays: England
ID NLM: 101487380
Informations de publication
Date de publication:
07 12 2022
07 12 2022
Historique:
revised:
05
09
2022
received:
20
06
2022
accepted:
05
09
2022
pubmed:
1
11
2022
medline:
15
12
2022
entrez:
31
10
2022
Statut:
ppublish
Résumé
Tuberculosis (TB) is a leading cause of morbidity and mortality from a single infectious agent, despite being preventable and curable. Early and accurate diagnosis of active TB is critical to both enhance patient care, improve patient outcomes, and break Mycobacterium tuberculosis (Mtb) transmission cycles. In 2020 an estimated 9.9 million people fell ill from Mtb, but only a little over half (5.8 million) received an active TB diagnosis and treatment. The World Health Organization has proposed target product profiles for biomarker- or biosignature-based diagnostics using point-of-care tests from easily accessible specimens such as urine or blood. Here we review and summarize progress made in the development of pathogen- and host-based biomarkers for active TB diagnosis. We describe several unique patient populations that have posed challenges to development of a universal diagnostic TB biomarker, such as people living with HIV, extrapulmonary TB, and children. We also review additional limitations to widespread validation and utilization of published biomarkers. We conclude with proposed solutions to enhance TB diagnostic biomarker validation and uptake.
Identifiants
pubmed: 36314872
doi: 10.15252/emmm.202114088
pmc: PMC9728055
doi:
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14088Subventions
Organisme : NIAID NIH HHS
ID : T32 AI007291
Pays : United States
Informations de copyright
© 2022 The Authors. Published under the terms of the CC BY 4.0 license.
Références
Lancet. 2007 Jun 16;369(9578):2042-2049
pubmed: 17574096
Thorax. 2016 Sep;71(9):785-94
pubmed: 27146200
Am J Respir Crit Care Med. 2019 Dec 15;200(12):1531-1538
pubmed: 31381861
Eur Respir J. 2014 Aug;44(2):435-46
pubmed: 24696113
Clin Infect Dis. 2016 Apr 15;62(8):995-1001
pubmed: 26908793
PLoS One. 2016 Jan 25;11(1):e0147933
pubmed: 26808299
N Engl J Med. 2022 Apr 21;386(16):1490-1493
pubmed: 34986295
Cochrane Database Syst Rev. 2018 Aug 27;8:CD012768
pubmed: 30148542
Sci Rep. 2019 Nov 12;9(1):16587
pubmed: 31719625
Nat Commun. 2018 Dec 6;9(1):5208
pubmed: 30523338
Clin Infect Dis. 2015 Oct 15;61Suppl 3:S155-9
pubmed: 26409277
Clin Infect Dis. 2012 Dec;55(11):1532-49
pubmed: 22942202
Front Microbiol. 2019 Jun 26;10:1441
pubmed: 31297103
Commun Med (Lond). 2022;2(1):
pubmed: 35342900
Sci Rep. 2020 Nov 11;10(1):19527
pubmed: 33177551
PLoS Med. 2016 Oct 25;13(10):e1002152
pubmed: 27780211
PLoS One. 2011 Jan 21;6(1):e16425
pubmed: 21283655
PLoS One. 2015 Jun 08;10(6):e0126018
pubmed: 26053546
Front Microbiol. 2019 Dec 18;10:2789
pubmed: 31921004
JCI Insight. 2020 Sep 17;5(18):
pubmed: 32780727
Eur J Case Rep Intern Med. 2020 Jul 06;7(10):001737
pubmed: 33083351
BMC Infect Dis. 2020 Jul 25;20(1):543
pubmed: 32711457
Lancet Infect Dis. 2021 Mar;21(3):354-365
pubmed: 33508224
PLoS One. 2021 Aug 31;16(8):e0256883
pubmed: 34464413
PLoS One. 2014 Mar 21;9(3):e92308
pubmed: 24658103
Paediatr Respir Rev. 2020 Nov;36:52-56
pubmed: 32624357
Biomed J. 2022 Aug;45(4):654-664
pubmed: 34314900
Front Immunol. 2019 Sep 11;10:1968
pubmed: 31572351
PLoS Med. 2013 Oct;10(10):e1001538
pubmed: 24167453
N Engl J Med. 2021 Dec 9;385(24):2271-2280
pubmed: 34879450
Nat Microbiol. 2019 May;4(5):748-758
pubmed: 30804546
Obstet Gynecol. 2020 Jun;135(6):1444-1453
pubmed: 32459437
Int J Infect Dis. 2020 Oct;99:473-481
pubmed: 32800854
Sci Rep. 2020 Mar 2;10(1):3844
pubmed: 32123229
Eur Respir J. 2021 Nov 4;58(5):
pubmed: 34049948
Am J Reprod Immunol. 2010 Jun;63(6):425-33
pubmed: 20367629
Int J Mycobacteriol. 2014 Sep;3(3):205-10
pubmed: 26786489
J Clin Microbiol. 2017 Oct;55(10):3057-3071
pubmed: 28794177
BMC Health Serv Res. 2020 Mar 4;20(1):162
pubmed: 32131814
Mol Med Rep. 2015 Nov;12(5):6561-7
pubmed: 26324150
Trop Med Infect Dis. 2019 Mar 31;4(2):
pubmed: 30935095
Lancet Infect Dis. 2012 Mar;12(3):201-9
pubmed: 22015305
J Clin Tuberc Other Mycobact Dis. 2021 Nov 05;25:100284
pubmed: 34805557
Lancet Infect Dis. 2014 Oct;14(10):931-8
pubmed: 25185458
N Engl J Med. 2014 May 01;370(18):1712-1723
pubmed: 24785206
Clin Infect Dis. 2020 Nov 5;71(8):1905-1911
pubmed: 31665254
Trends Biotechnol. 2004 Aug;22(8):411-6
pubmed: 15283986
Front Microbiol. 2018 Mar 29;9:602
pubmed: 29651283
Thorax. 2019 Dec;74(12):1161-1167
pubmed: 31611342
Tuberculosis (Edinb). 2017 Jan;102:55-67
pubmed: 28061953
Hypertension. 2021 Apr;77(4):1029-1035
pubmed: 33583200
Public Health. 2016 Sep;138:101-7
pubmed: 27137870
Infect Immun. 2020 Feb 20;88(3):
pubmed: 31871103
Cytokine. 2019 Nov;123:154773
pubmed: 31299414
EBioMedicine. 2015 Jul 30;2(9):1160-8
pubmed: 26501113
Lancet Glob Health. 2020 Sep;8(9):e1132-e1141
pubmed: 32673577
EMBO Mol Med. 2022 Dec 7;14(12):e14088
pubmed: 36314872
Curr Opin Microbiol. 2017 Oct;39:64-72
pubmed: 29032348
Biomark Med. 2017 Nov;11(11):1017-1029
pubmed: 29039217
Front Immunol. 2020 Mar 11;11:419
pubmed: 32218787
Clin Infect Dis. 2022 Jul 6;74(12):2136-2141
pubmed: 34550342
Lancet Infect Dis. 2021 Mar;21(3):366-375
pubmed: 33508221
Eur Respir J. 2020 Mar 20;55(3):
pubmed: 31862768
Tuberculosis (Edinb). 2018 Dec;113:153-162
pubmed: 30514497
J Acquir Immune Defic Syndr. 2017 May 1;75(1):128-136
pubmed: 28141782
Sci Rep. 2017 Jul 19;7(1):5839
pubmed: 28724962
Sci Rep. 2018 Feb 8;8(1):2675
pubmed: 29422548
PLoS One. 2019 Jul 2;14(7):e0218890
pubmed: 31265470
J Infect Dis. 2020 Apr 27;221(10):1647-1658
pubmed: 31796955
Front Public Health. 2021 Nov 25;9:757133
pubmed: 34900905
Lancet Infect Dis. 2022 Apr;22(4):507-518
pubmed: 34800394
J Clin Microbiol. 2022 Aug 17;60(8):e0015522
pubmed: 35861529
J Infect Dis. 2012 May 15;205 Suppl 2:S216-27
pubmed: 22448018
J Clin Microbiol. 2018 Nov 27;56(12):
pubmed: 30257899
IARC Sci Publ. 2011;(163):143-61
pubmed: 22997860
PLoS One. 2014 Jun 11;9(2):e98938
pubmed: 24918450
Lancet Infect Dis. 2018 Jan;18(1):76-84
pubmed: 29198911
Eur Respir J. 2016 Jun;47(6):1873-6
pubmed: 27076596
Lancet Respir Med. 2016 Mar;4(3):213-24
pubmed: 26907218
PLoS One. 2016 Oct 5;11(10):e0162220
pubmed: 27706152
PLoS One. 2020 Aug 21;15(8):e0237574
pubmed: 32822359
EBioMedicine. 2022 Jan;75:103787
pubmed: 34968761
Brief Bioinform. 2019 Sep 27;20(5):1795-1811
pubmed: 30084865
Infect Drug Resist. 2022 Jan 27;15:285-294
pubmed: 35115796
Oncotarget. 2016 Sep 6;7(36):57581-57592
pubmed: 27557501
Microbiol Insights. 2018 Nov 27;11:1178636118813367
pubmed: 30505151
Lancet Glob Health. 2021 Jun;9(6):e841-e853
pubmed: 33862012
Front Cell Infect Microbiol. 2022 Feb 24;12:792617
pubmed: 35281437
Infection. 2014 Aug;42(4):649-54
pubmed: 24652106
Int J Infect Dis. 2021 Nov;112:205-211
pubmed: 34517050
Sci Rep. 2020 Mar 2;10(1):3825
pubmed: 32123207
Lancet. 2016 Jun 4;387(10035):2312-2322
pubmed: 27017310
Tuberculosis (Edinb). 2019 May;116:37-43
pubmed: 31153517
Clin Infect Dis. 2021 Nov 2;73(9):e3555-e3562
pubmed: 32720695
Eur Respir J. 2020 Aug 13;56(2):
pubmed: 32513784
JAMA Netw Open. 2019 Feb 1;2(2):e187617
pubmed: 30735231
Tuberculosis (Edinb). 2018 Jan;108:26-34
pubmed: 29523324
BMC Infect Dis. 2013 Oct 29;13:506
pubmed: 24168695
Front Immunol. 2021 Jun 08;12:676980
pubmed: 34168648
Clin Infect Dis. 2021 Aug 2;73(3):e830-e841
pubmed: 32936877
J Thorac Oncol. 2021 Apr;16(4):537-545
pubmed: 33545385
Lancet Infect Dis. 2018 Jul;18(7):e199-e210
pubmed: 29580818
Eur Respir J. 2019 Sep 12;54(3):
pubmed: 31221810